$ICVX News
Last published 2y ago
- 2y agoICVXFrazier Life Sciences Adds Industry Veteran and Serial Dealmaker, Adam Simpson, to Company Creation TeamBusiness WireSimpson has helped build 11 companies that have been acquired or gone public, most recently serving as CEO of Icosavax Frazier Life Sciences (FLS), a longstanding investment firm investing in innovative
- 2y agoICVXLYELSANACHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)GlobeNewswirePRESS RELEASE CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) LONDON – 19 March 2024 -- CHARM Therapeutics ("CHARM", "The Company"), a 3D deep-learning research company discovering and
- 2y agoICVXCSTRAVROCALBKuehn Law Encourages ICVX, CSTR, AVRO, and CALB Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoHAHARPICVXPXDKuehn Law Encourages HA, ICVX, PXD, and HARP Investors to Contact Law FirmGlobeNewswireNEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoPXDIMGNHAICVXKuehn Law Encourages PXD, IMGN, HA and ICVX Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoEGLEICVXRAINAYXKuehn Law Encourages EGLE, ICVX, RAIN, and AYX Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoAZNICVXAstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II DataBusiness WireBuilding on expertise in RSV prevention, acquisition will accelerate ambition to deliver portfolio of protective interventions to address high unmet needs in infectious diseases AstraZeneca has entered into a
- 2y agoICVXIcosavax, Inc. Announces Agreement to be Acquired by AstraZenecaGlobeNewswire- Icosavax stockholders to receive $15.00 per share in cash at closing plus non-tradeable contingent value right (CVR) of up to $5.00 per share - - Representing a total equity value of up to $1.1 billion including the
- 2y agoICVXIcosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older AdultsGlobeNewswire– IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV, and was generally well tolerated, consistent with prior IVX-A12 Phase 1 data – SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc.
- 2y agoICVXIcosavax Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswire- Reported positive twelve-month durability data and initial proof-of-concept for revaccination with IVX-121 against RSV - - IVX-A12 (RSV+hMPV) Phase 2 topline interim data expected by end of 2023 - - Completed
- 3y agoICVXIcosavax to Participate in the Jefferies London Healthcare ConferenceGlobeNewswireSEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious
- 3y agoICVXIcosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) ConferenceGlobeNewswireSEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious
- 3y agoICVXIcosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023GlobeNewswireSEATTLE, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious
- 3y agoICVXIcosavax Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswire- Positive topline interim Phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults - - Positive twelve-month immunogenicity data and initial proof-of-concept for revaccination
- 3y agoICVXIcosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination PotentialGlobeNewswire- In new data from Icosavax's IVX-121 Phase 1b extension trial in older adults, GMTs against RSV through day 365 persisted at ~45-70% of the GMTs at day 28 (for 75 and 250 µg unadjuvanted dosages) - - Data provide
- 3y agoICVXIcosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older AdultsGlobeNewswire- Phase 2 topline interim results expected in 1Q 2024 - - 6-month durability data for Phase 1 trial of IVX-A12 also expected in 1Q 2024 - SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc.
- 3y agoICVXIcosavax Announces $67.8 Million Registered Direct Offering of Common StockGlobeNewswireSEATTLE, May 22, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious
- 3y agoICVXIcosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older AdultsGlobeNewswire– IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV in older adults – – IVX-A12 was generally well tolerated with no vaccine-related SAEs – – First demonstration of hMPV vaccine immunogenicity
- 3y agoICVXIcosavax Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswire- IVX-A12 (RSV+hMPV) Phase 1 topline interim data expected in 2Q 2023 - - Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 - - Cash and cash equivalents, restricted cash, and short-term investments of $197.7M at
- 3y agoICVXIcosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewswire- FDA granted Fast Track Designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine candidate - - Completed dosing in ongoing Phase 1 study of IVX-A12; topline
- 3y agoICVXIcosavax to Participate in the Upcoming Healthcare ConferencesGlobeNewswireSEATTLE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious
- 3y agoICVXIcosavax Granted FDA Fast Track Designation for IVX-A12GlobeNewswireSEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious
- 3y agoICVXIcosavax Provides Corporate Update and Anticipated Milestones for 2023GlobeNewswire- Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of potential differentiation on durability with company's VLP platform - - Phase 1 study of IVX-A12 (a bivalent
- 3y agoICVXIcosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month TimepointGlobeNewswire- In new data from Phase 1/1b study, IVX-121 showed sustained immunologic response at six months; geometric mean titers (GMT) against RSV-A through day 180 persisting at 64-98% of the GMTs at day 28 in older adults - -
- 3y agoICVXIcosavax to Participate in the Evercore ISI HealthCONx ConferenceGlobeNewswireSEATTLE, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious
- 4y agoICVXIcosavax to Participate in in Upcoming Investor ConferencesGlobeNewswireSEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious
- 4y agoICVXIcosavax Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older AdultsGlobeNewswire- IVX-A12 is the first combination bivalent vaccine candidate against both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) to reach clinical stage - - Phase 1 topline interim results expected in mid-2023 - - Phase 2 initiatio
- 4y agoICVXIcosavax Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswire– Announced positive topline interim Phase 1/1b results for VLP vaccine candidate IVX-121 against respiratory syncytial virus (RSV) - – Icosavax plans to file an IND and initiate a Phase 1 trial for IVX-A12, a combination bivalent RSV + human
- 4y agoICVXIcosavax Announces Results from IVX-411 Drug Product Investigation and Outlines Additional Corporate MilestonesGlobeNewswire- Antigen component of IVX-411 found to be unstable; issue specific to molecule, with no evidence of read-through to other Icosavax programs - - Now focused on a bivalent strategy for COVID-19 candidate development displaying computationally engineere
- 4y agoICVXIcosavax to Participate in the William Blair Biotech Focus ConferenceGlobeNewswireSEATTLE, July 06, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-
- 4y agoICVXIcosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSVGlobeNewswire- IVX-121 demonstrated robust immunologic response to RSV, with comparable Geometric Mean Titer (GMT) levels achieved at Day 28 in both young and older adult groups - - IVX-121 was generally well tolerated with no vaccine-related SAEs - - Provides
- 4y agoICVXIcosavax to Participate in the Jefferies Healthcare ConferenceGlobeNewswireSEATTLE, June 01, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle platform technology to develop combination vaccines against infectious diseases, with an initial focus on
- 4y agoICVXIcosavax Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswire- Enrollment completed in older adults portion of Phase 1/1b trial of IVX-121, a virus like particle (VLP) vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen - - Topline, interim Phase 1/1b data for IVX-1
- 4y agoICVXIcosavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewswire- Completed dosing in older adults portion of Phase 1/1b clinical trial for IVX-121, a VLP vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen - - Company anticipates topline, interim data for RSV le
- 4y agoICVXIcosavax Announces Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2GlobeNewswire- Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than expected and inconsistent with known data on company's platform and VLP technology; end-to-end drug product investigation underway - - Data ind
- 4y agoICVXIcosavax to Participate in the Cowen 42nd Annual Health Care ConferenceGlobeNewswireSEATTLE, March 02, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced that the comp
- 4y agoICVXIcosavax Provides Corporate Update and Anticipated Milestones for 2022GlobeNewswireSEATTLE, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today provided a corporate upd
- 4y agoICVXIcosavax Appoints Dr. John Shiver to Board of DirectorsGlobeNewswireSEATTLE, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointmen
- 4y agoADGIICVXIKNAIMGO+5Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science CompaniesPR NewswireBOSTON, Dec. 17, 2021 /PRNewswire/ -- Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced it has closed its seventh and largest fund with $650 million in limited part
- 4y agoICVXIcosavax Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswire- Initiated a Phase 1/1b clinical trial for IVX-121, a virus like particle (VLP) vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen - - Completed dosing in ongoing Phase 1/2 clinical trial for IVX-411,
- 5y agoICVXIcosavax to Participate in Upcoming Investor ConferencesGlobeNewswireSEATTLE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-
- 5y agoICVXIcosavax Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswire- Initiated a Phase 1/2 clinical trial for IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain - - Initiated a Phase 1/1b clinical trial for IVX-121, a VLP displaying a Respiratory Syncytial Virus (RSV) stabilize
- 5y agoICVXIcosavax Appoints Elizabeth Bekiroğlu to General CounselGlobeNewswireSEATTLE, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointme
- 5y agoICVXIcosavax Initiates Phase 1/1b Trial of VLP Vaccine Candidate Against Respiratory Syncytial VirusGlobeNewswireSEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the initiatio
- 5y agoBASEHOODICVXAdams Street Partners Growth Equity Strategy Participates in Three High-Profile Public Offerings In Seven DaysBusiness WireAdams Street Partners, a private markets investment firm with $45 billion in assets under management, announced today that within a 7-day period last week three companies within its Growth Equity portfolio launched initial public offerings (IPOs). This
- 5y agoICVXIcosavax Mourns Sudden Passing of Tadataka Yamada, M.D. Chairman of the Company's Board of DirectorsGlobeNewswireSEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-
- 5y agoICVXIcosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireSEATTLE, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-
- 5y agoICVXIcosavax Announces Pricing of Upsized Initial Public OfferingBusiness WireIcosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today anno